Melane Sampson, Author at BioTuesdays

Developments

USPTO grants OS NOA covering manufacturing of OST-HER2

OS Therapies (NYSE-A:OSTX) has announced that it has received a notice of allowance from the US Patent & Trademark Office (USPTO) covering the manufacturing methods required for OST-HER2. According to OS, the USPTO...

February 20, 2025

Developments

Hemostemix Licences CytoImmune’s BioReactor Technologies

Hemostemix (TSXV:HEM; OTCQB:HMTXF) has announced that it has secured an arm’s length perpetual, royalty-free global license to CytoImmune’s BioReactor stem cell technologies. Subject to the TSXV Exchange acceptance...

February 20, 2025

Developments

MOBILion showcases new mass spectrometry approach at US HUPO conference

Closely held MOBILion Systems has announced its participation in the 21st annual US HUPO conference this month in Philadelphia. The company will showcase its new Parallel Accumulation with Mobility Aligned Fragmentation...

February 19, 2025

Developments

AHN launches Ekso Bionics’ transformational robotic exoskeleton technology

Non-profit Allegheny Health Network (AHN) has introduced the groundbreaking EksoNR, a wearable, full-body robotic exoskeleton that assists patients recovering from neurological injury or disease. The weight-bearing...

February 19, 2025

Developments

First New Mexico Hospital leverages Perimeter’s AI-driven, wide field OCT margin visualization technology during breast cancer surgery

Perimeter Medical Imaging AI (TSX-V:Pink; OTC:PYNKF) announced that CHRISTIS St. Vincent is the first hospital in New Mexico to use its optical coherence technology (OCT), S-Series OCT, to visualize tissue margins...

February 19, 2025

Executive Moves

Industry vet John Calcagnini joins Mesirow as a managing director, healthcare sector

Mesirow Investment Banking has announced the appointment of John Calcagnini as a managing director in its investment banking group based in Los Angeles. Mr. Calgagnini will co-lead the company’s healthcare sector...

February 19, 2025

Feature

Climb driving transformational therapies in immune-mediated diseases

Climb Bio (NASDAQ:CLYM) is advancing a pipeline of best-in-class, patient-tailored therapeutics to address the unmet needs of complex and clinically-diverse immune-mediated diseases.

February 18, 2025

Developments

Theratechnologies resumes U.S. supply of EGRIFTA SV for HIV

Theratechnologies (TSX:TH; NASDAQ:THTX) announced that the FDA has granted approval for the company to resume U.S. distribution of its tesamorelin injection, EGRIFTA SV, for patients with HIV. According to the company...

February 14, 2025

Developments

Pliant assembles expert panel to review bexotegrast trial data in IPF

Pliant Therapeutics (NASDAQ:PLRX) announced that, following a recommendation by the Data Safety Monitoring Board (DSMB), it will convene an independent panel of experts in pulmonary diseases and biostatistics to review...

February 13, 2025

Developments

Top-tier journal publishes NKGen’s trial results on troculeucel in AD

NKGen Biotech (NASDAQ:NKGN) announced that results from its initial dose-escalation Phase 1 trial of troculeucel for the treatment of Alzheimer’s disease (AD) have been published in the international, peer-reviewed...

February 13, 2025

Author - Melane Sampson

USPTO grants OS NOA covering manufacturing of OST-HER2

Hemostemix Licences CytoImmune’s BioReactor Technologies

MOBILion showcases new mass spectrometry approach at US HUPO conference

AHN launches Ekso Bionics’ transformational robotic exoskeleton technology

First New Mexico Hospital leverages Perimeter’s AI-driven, wide field OCT margin visualization technology during breast cancer surgery

Industry vet John Calcagnini joins Mesirow as a managing director, healthcare sector

Climb driving transformational therapies in immune-mediated diseases

Theratechnologies resumes U.S. supply of EGRIFTA SV for HIV

Pliant assembles expert panel to review bexotegrast trial data in IPF

Top-tier journal publishes NKGen’s trial results on troculeucel in AD

Subscribe